Delfini Lisa
SEC CIK 1873253 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TRVI | Trevi Therapeutics, Inc. | CFO | 59.7K | — | $45.0K | 21 | 2023-02-13 | 2025-01-07 |
Most active insiders at TRVI, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Heffernan Michael Thomas | Dir | — | $595.8K |
| 2 | Galletta Christopher | See Remarks | — | — |
Delfini Lisa made no open-market trades at TRVI in the last 12 months.
Transactions 21
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-01-10 | 2025-01-07+ | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | M - OptEx | $0.51 | +6,000 | 59.7K | +11% | +$3,060 |
| D | 2024-05-24 | 2024-05-22 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | M - OptEx | $0.51 | +16.0K | 57.6K | +39% | +$8,182 |
| D | 2024-05-24 | 2024-05-22 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | S - Sale+OE | $2.64 | -4,350 | 53.3K | -8% | -$11.5K |
| D | 2023-10-12 | 2023-10-11 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | S - Sale+OE | $2.02 | -785 | 35.9K | -2% | -$1,586 |
| D | 2023-10-12 | 2023-10-11 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | M - OptEx | $0.51 | +2,292 | 36.7K | +7% | +$1,169 |
| D | 2023-09-13 | 2023-09-11 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | M - OptEx | $0.51 | +2,291 | 35.1K | +7% | +$1,168 |
| D | 2023-09-13 | 2023-09-11 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | S - Sale+OE | $2.20 | -711 | 34.4K | -2% | -$1,564 |
| D | 2023-08-14 | 2023-08-11 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | M - OptEx | $0.51 | +2,292 | 33.5K | +7% | +$1,169 |
| D | 2023-08-14 | 2023-08-11 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | S - Sale+OE | $2.36 | -682 | 32.8K | -2% | -$1,610 |
| D | 2023-07-12 | 2023-07-11 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | S - Sale+OE | $2.34 | -687 | 31.2K | -2% | -$1,608 |
| D | 2023-07-12 | 2023-07-11 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | M - OptEx | $0.51 | +2,292 | 31.9K | +8% | +$1,169 |
| D | 2023-06-14 | 2023-06-12 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | M - OptEx | $0.51 | +2,291 | 30.2K | +8% | +$1,168 |
| D | 2023-06-14 | 2023-06-12 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | S - Sale+OE | $2.64 | -610 | 29.6K | -2% | -$1,610 |
| D | 2023-05-15 | 2023-05-11 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | S - Sale+OE | $2.89 | -562 | 27.9K | -2% | -$1,624 |
| D | 2023-05-15 | 2023-05-11 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | M - OptEx | $0.51 | +2,291 | 28.5K | +9% | +$1,168 |
| D | 2023-04-12 | 2023-04-11 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | S - Sale+OE | $1.84 | -840 | 26.2K | -3% | -$1,546 |
| D | 2023-04-12 | 2023-04-11 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | M - OptEx | $0.51 | +2,292 | 27.0K | +9% | +$1,169 |
| D | 2023-03-15 | 2023-03-13 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | M - OptEx | $0.51 | +2,291 | 25.6K | +10% | +$1,168 |
| D | 2023-03-15 | 2023-03-13 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | S - Sale+OE | $1.75 | -892 | 24.7K | -3% | -$1,561 |
| D | 2023-02-15 | 2023-02-13 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | M - OptEx | $0.51 | +27.5K | 31.8K | +638% | +$14.0K |
| D | 2023-02-15 | 2023-02-13 | TRVI | Trevi Therapeutics, Inc. | Delfini Lisa | CFO | S - Sale+OE | $2.45 | -8,474 | 23.3K | -27% | -$20.8K |
Purchase Sale Sale after option exercise All abbreviations